Robert W Baird
View Older Stories View More Recent Stories
-
Gibraltar Industries to Present at Robert W. Baird & Co. 2011 Industrial Conference
-
Baird Downgrades Hub Group (HUBG) to Neutral
-
Baird Downgrades Landstar System (LSTR) to Neutral
-
PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
-
Pall Corporation to Present at Baird 2011 Industrial Conference
-
ADA-ES Commences Public Offering of Common Stock
-
RiverFront Investment Group Relocates Headquarters to Downtown Richmond
-
Generac CEO to Present at Baird 2011 Industrial Conference
-
Baird Upgrades Duke Realty (DRE) to Outperform
-
Notable Analyst Rating Changes 10/21: (STX) (WYNN) (FST) Upgraded; (BHP) (HBAN) (FLIR) Downgraded
-
Baird Upgrades Seagate Technology (STX) to Outperform
-
Baird maintains an 'Outperform' on Vertex (VRTX); Building a Franchise Around Incivek; Pipeline Looks Like A Call Option
-
Baird Maintains an 'Outperform' on Cubist Pharmaceuticals (CBST); Q3-11: Sizable Beat and Raise
-
Baird Maintains a 'Neutral' on Amylin Pharmaceuticals (AMLN); Q3-11: Continued Revenue Stabilization and a New Indication for Byetta
-
Baird Upgrades UniFirst Corp (UNF) to Outperform
-
Baird Upgrades DaVita (DVA) to Outperform
-
Google (GOOG) Q3 Results Smash Expectations; Analysts Consider the Beat, Remain Bullish
-
Notable ETF Movers of the Day 10/13: (VXX) (SMH) (UUP) Higher; (USO) (XLF) (EWZ) Lower
-
Baird Maintains a 'Neutral' on Regeneron Pharma (REGN) Following Roche's Q311 Lucentis Update
-
Notable Analyst Rating Changes 10/13: (BRCM) (WSM) (LPX) Higher; (ALTR) (LM) (KR) Lower
-
Broadcom (BRCM) volatility elevated on tight five-month range into Q3
-
Baird Upgrades Broadcom (BRCM) to Outperform
-
Baird Downgrades Altera (ALTR) to Neutral
-
Baird Maintains an 'Outperform' on Onyx Pharmaceuticals (ONXX); Hitting Pay Dirt on Bayer Settlement and Nexavar Restructuring
-
Baird Maintains an 'Outperform' on Amgen (AMGN); New ESA Label More Impactful than We'd Thought - Lowering EPO, Again
-
Baird Downgrades Accenture plc (ACN) to Neutral
-
Baird Cuts IBKC, BKYF, MBFI, CNFL, FFBC, WTFC, FMBI to Neutral, BOH to Underperform
-
Baird Reiterates a 'Neutral' on Acorda Therapeutics (ACOR); Latest MS Survey Indicates Ampyra Still Flat-Lining
-
Baird Starts GameStop (GME) at Outperform, $29 Price Target
-
Baird Starts Take-Two Interactive (TTWO) at Neutral, $15 Price Target
-
Baird Starts Electronic Arts (ERTS) at Neutral, $25 Price Target
-
Baird Starts Activision Blizzard (ATVI) at Outperform, $15 Price Target
-
Baird Downgrades Mistras Group (MG) to Neutral
-
Baird Upgrades Watsco (WSO) to Outperform
-
Baird Downgrades WW Grainger (GWW) to Neutral
-
Baird Downgrades Fastenal (FAST) to Neutral
-
Baird Downgrades Comverge (COMV) to Neutral
-
Baird Starts Fortune Brands Home (FBHS) at Neutral
-
Baird Downgrades KiOR, Inc. (KIOR) to Underperform
-
Baird Reiterates a 'Neutral' on Regeneron Pharma (REGN); Kills Us to Sit on the Fence, But New Survey Shows That's the Best Place
-
Baird Reiterates an 'Outperform' on Endocyte (ECYT); Doxil Shortage May Present a Real Risk to PROCEED Timelines
-
Notable Analyst Rating Changes 09/27: (POT) (SAFM) (KIM) Upgraded; (SKM) (CTCM) (HUN) Downgraded
-
Baird Reiterates a 'Neutral' on Alexion Pharmaceuticals (ALXN); Raising Estimates and Target Again
-
Baird Upgrades Kimco Realty (KIM) to Neutral
-
Baird Upgrades Tortoise Energy Infrastructure (TYG) to Outperform
-
Baird Reiterates a 'Neutral' on Alexion Pharmaceuticals (ALXN); Regulatory Two-Fer; aHUS Indication Cleared in US/EU
-
Baird Maintains an 'Outperform' on BioMarin Pharmaceutical (BMRN); Valuation Still Attractive, Remains a Core Holding
-
Several Firms Begin Coverage on SandRidge Permian Trust (PER)
-
Baird Starts SandRidge Permian Trust (PER) at Outperform
-
Mascoma Corp. Files $100M IPO
